Injectable poly-L-lactic acid for cosmetic enhancement: Learning from the European experience

Journal of the American Academy of Dermatology

Volumn 61, Issue 2, 2009, Pages 281-293

  Butterwick, Kimberly ^a   Lowe, Nicholas J ^b  

^a La Jolla Spine Institute   (United States)

^b Clinical Research Specialists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; POLYLACTIC ACID;

ANAPHYLAXIS; BIOMEDICAL TECHNOLOGY ASSESSMENT; BLEEDING; CLINICAL TRIAL; COLLAGEN SYNTHESIS; DERMIS; ECCHYMOSIS; ERYTHEMA; ESTHETICS; FACE; FIBROBLAST; GRANULOMA; HEMATOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; INJECTION PAIN; INJECTION SITE EDEMA; LIPOATROPHY; OUTCOME ASSESSMENT; PAIN; PAPULE; PRIORITY JOURNAL; REVIEW; SKIN BRUISING; SKIN NODULE; SKINFOLD THICKNESS;

COSMETIC TECHNIQUES; ESTHETICS; EUROPE; FEMALE; HUMANS; INJECTIONS, INTRADERMAL; LACTIC ACID; MALE; PATIENT SATISFACTION; POLYMERS; REJUVENATION; RISK ASSESSMENT; SKIN AGING; TREATMENT OUTCOME; UNITED STATES;

EID: 67650141101     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2008.11.881     Document Type: Review

References (36)

1. American Academy of Facial Plastic Reconstructive Surgery. 2006 Membership survey: trends in facial plastic surgery. Available from: URL: http://www.aafprs.org/media/stats_polls/aafprsMedia2006.pdf. Accessed January 19, 2009
2. Bergeret-Galley C. Comparison of resorbable soft tissue fillers. Aesthetic Surg J 24 (2004) 33-46
3. Wang F., Garza L.A., Kang S., Varani J., Orringer J.S., Fisher G.J., et al. In vivo stimulation of de novo collagen production caused by cross-linked hyaluronic acid dermal filler injections in photodamaged human skin. Arch Dermatol 143 (2007) 155-163
4. Werschler W.P., and Weinkle S. Longevity of effects of injectable products for soft-tissue augmentation. J Drugs Dermatol 4 (2005) 20-27
5. Broder K.W., and Cohen S.R. An overview of permanent and semipermanent fillers. Plast Reconstr Surg 118 Suppl (2006) 7-14S
6. Lemperle G., Romano J.J., and Busso M. Soft tissue augmentation with artecoll: 10-year history, indications, techniques, and complications. Dermatol Surg 29 (2003) 573-587
7. Marmur E.S., Phelps R., and Goldberg D.J. Clinical, histologic and electron microscopic findings after injection of a calcium hydroxylapatite filler. J Cosmet Laser Ther 6 (2004) 223-226
8. Silvers S.L., Eviatar J.A., Echavez M.I., and Pappas A.L. Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 118 Suppl (2006) 34-45S
9. Sklar J.A., and White S.M. Radiance FN: a new soft tissue filler. Dermatol Surg 30 (2004) 764-768
10. Burgess C.M., and Quiroga R.M. Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol 52 (2005) 233-239
11. Mest D.R., and Humble G. Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. Dermatol Surg 32 (2006) 1336-1345
12. Moyle G.J., Brown S., Lysakova L., and Barton S.E. Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. HIV Med 7 (2006) 181-185
13. Valantin M.A., Aubron-Olivier C., Ghosn J., Laglenne E., Pauchard M., Schoen H., et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 17 (2003) 2471-2477
14. Lam S.M., Azizzadeh B., and Graivier M. Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg 118 Suppl (2006) 55-63S
15. Lowe N.J., Maxwell C.A., and Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg 31 (2005) 1616-1625
16. Guaraldi G., Orlando G., De Fazio D., De Lorenzi I., Rottino A., De Santis G., et al. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study. Antivir Ther 10 (2005) 753-759
17. Vleggaar D. Soft-tissue augmentation and the role of poly-L-lactic acid. Plast Reconstr Surg 118 Suppl (2006) 46-54S
18. Gogolewski S., Jovanovic M., Perren S.M., Dillon J.G., and Hughes M.K. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res 27 (1993) 1135-1148
19. Vleggaar D. Facial volumetric correction with injectable poly-L-lactic acid. Dermatol Surg 31 (2005) 1511-1518
20. Vleggaar D., and Bauer U. Facial enhancement and the European experience with Sculptra (poly-l-lactic acid). J Drugs Dermatol 3 (2004) 542-547
21. Bauer U. Improvement of facial aesthetics at 40 months with injectable poly-L-lactic acid (PLLA) (2004), International Society of Aesthetic Plastic Surgery, Houston
22. Lewis D. Controlled release of bioactive agents from lactide/glycolide polymers. In: Chasin M., and Langer R. (Eds). Biodegradable polymers as drug delivery systems (1990), Marcel Dekker Inc, New York
23. Woerle B., Hanke C.W., and Sattler G. Poly-L-lactic acid: a temporary filler for soft tissue augmentation. J Drugs Dermatol 3 (2004) 385-389
24. Borelli C., Kunte C., Weisenseel P., Thoma-Greber E., Korting H.C., and Konz B. Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol 18 (2005) 273-278
25. Moyle G.J., Lysakova L., Brown S., Sibtain N., Healy J., Priest C., et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 5 (2004) 82-87
26. Lafaurie M., Dolivo M., Porcher R., Rudant J., Madelaine I., and Molina J.M. Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients. J Acquir Immune Defic Syndr 38 (2005) 393-398
27. Andre P., Lowe N.J., Parc A., Clerici T.H., and Zimmermann U. Adverse reactions to dermal fillers: a review of European experiences. J Cosmet Laser Ther 7 (2005) 171-176
28. Bodokh I., and Simonet P. Polylactic acid injections (Newfill) in the treatment of facial lipodystrophy in HIV-positive patients. [French]. Ann Dermatol Venereol 133 (2006) 429-432
29. Piquet M., Brignol L., Chatelain B., Rey D., Ricbourg B., and Meyer C. Polylactic acid injections: usefulness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy. [French]. Rev Stomatol Chir Maxillofac 108 (2007) 496-504
30. Salles A.G., Lotierzo P.H., Gimenez R., Camargo C.P., and Ferreira M.C. Evaluation of the poly-L-lactic acid implant for treatment of the nasolabial fold: 3-year follow-up evaluation. Aesthetic Plast Surg 108 (2008) 496-504
31. Hanke C.W., and Redbord K.P. Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. J Drugs Dermatol 6 (2007) 123-128
32. Engelhard P., Humble G., and Mest D. Safety of Sculptra: a review of clinical trial data. J Cosmet Laser Ther 7 (2005) 201-205
33. Ascher B., Coleman S., Alster T., Bauer U., Burgess C., Butterwick K., et al. Full scope of effect of facial lipoatrophy: a framework of disease understanding. Dermatol Surg 32 (2006) 1058-1069
34. Lowe N.J., Maxwell C.A., Lowe P., Shah A., and Patnaik R. Injectable poly-l-lactic acid: 3 years of aesthetic experience. Dermatol Surg 35 Suppl 1 (2009) 344-349
35. Sculptra product information. Bridgewater, NJ: Dermik Laboratories, a business of Sanofi-Aventis US LLC. 2006. Available from: http://products.sanofi-aventis.us/sculptra/sculptra.html. Accessed January 19, 2009
36. Lowe N. Optimizing poly-L-lactic acid use. J Cosmet Las Ther 10 (2008) 1-4